Noon Academy
Series B in 2023
Noon Academy is a prominent edtech company based in Riyadh, Saudi Arabia, with additional offices in Cairo, Egypt, and Bengaluru, India. Established in 2013, it operates an online learning platform that has served over 12 million students across the Middle East. The platform facilitates collaborative learning by allowing students to study in groups, compete with peers, and access on-demand tutoring. It offers a range of educational content, including free resources and subscription-based services for advanced materials and private tutoring. Noon Academy aims to enhance the learning experience by blending technology with peer-to-peer interactions, making education more engaging and accessible, especially for exam preparation. The company is committed to connecting students with the best teachers, regardless of location, thus expanding its impact in the region and beyond.
TruKKer is a technology-enabled truck aggregator based in Abu Dhabi, UAE, founded in 2016. The company operates a logistics and fleet management platform that simplifies road freight and logistics operations by integrating demand and supply for land freight services. TruKKer's platform connects shippers and carriers in real time, ensuring maximum utilization of available trucks and reducing overall transportation costs. The company's network, powered by real-time data analytics, enhances reliability and transparency while creating opportunities for data monetization and consolidated procurement. By offering end-to-end coverage and a comprehensive service portfolio, TruKKer facilitates cross-border transportation services for various end markets, benefiting both shippers and transporters alike.
Rutilea is an IT company focused on addressing social issues through open-source solutions. It has developed a zero-code task recognition system that enhances efficiency, quality, and safety in various business environments. Utilizing multimodal artificial intelligence, Rutilea's system accurately identifies tasks, facilitating data-driven decision-making and operational efficiency. This innovation enables factories and stores to automate their operations, thereby improving overall productivity. Through its commitment to advancing the concept of "AI teaching AI," Rutilea aims to redefine automation and streamline processes across industries.
Prokarium
Series B in 2020
Prokarium Limited is a biopharmaceutical company based in London, United Kingdom, specializing in the development of vaccination and cancer immunotherapy solutions through synthetic biology. Established in 2007, Prokarium focuses on creating innovative microbial immunotherapy treatments, particularly in the oncology sector. Its product pipeline includes Vaxonella, which is designed to stimulate immune responses by utilizing the unique properties of the gastrointestinal tract. Additionally, the company is developing vaccines for various infectious diseases, including Clostridium difficile, Chlamydia trachomatis, plague, and enteric fever. Prokarium's lead program is aimed at revolutionizing the treatment of bladder cancer by fostering immune-driven, long-lasting antitumor effects, thereby offering new therapeutic options for healthcare providers in combating cancer and infectious diseases.
SecuLetter
Series B in 2020
SecuLetter Co Ltd is a company that specializes in cybersecurity solutions designed to combat a range of cyber threats, including malware and phishing attacks. Utilizing hybrid approaches that combine both static and dynamic analysis, SecuLetter effectively detects unknown attacks, even when cybercriminals attempt to conceal malicious links and attachments. The company focuses on diagnosing and analyzing security vulnerabilities at the assembly level of non-executable files, enabling it to achieve a high detection rate for security threats and exploits. SecuLetter's primary business areas encompass email security, secure data transmission between networks, web service file security, document centralization, cloud support security, and security threat intelligence, ensuring comprehensive protection against emerging cyber threats.
SecuLetter
Series B in 2019
SecuLetter Co Ltd is a company that specializes in cybersecurity solutions designed to combat a range of cyber threats, including malware and phishing attacks. Utilizing hybrid approaches that combine both static and dynamic analysis, SecuLetter effectively detects unknown attacks, even when cybercriminals attempt to conceal malicious links and attachments. The company focuses on diagnosing and analyzing security vulnerabilities at the assembly level of non-executable files, enabling it to achieve a high detection rate for security threats and exploits. SecuLetter's primary business areas encompass email security, secure data transmission between networks, web service file security, document centralization, cloud support security, and security threat intelligence, ensuring comprehensive protection against emerging cyber threats.
Prokarium
Series A in 2018
Prokarium Limited is a biopharmaceutical company based in London, United Kingdom, specializing in the development of vaccination and cancer immunotherapy solutions through synthetic biology. Established in 2007, Prokarium focuses on creating innovative microbial immunotherapy treatments, particularly in the oncology sector. Its product pipeline includes Vaxonella, which is designed to stimulate immune responses by utilizing the unique properties of the gastrointestinal tract. Additionally, the company is developing vaccines for various infectious diseases, including Clostridium difficile, Chlamydia trachomatis, plague, and enteric fever. Prokarium's lead program is aimed at revolutionizing the treatment of bladder cancer by fostering immune-driven, long-lasting antitumor effects, thereby offering new therapeutic options for healthcare providers in combating cancer and infectious diseases.
Fastned B.V., founded in 2012 and headquartered in Amsterdam, constructs and operates fast-charging stations for electric vehicles (EVs) across Europe, with a significant presence in the Netherlands, Germany, the United Kingdom, France, Switzerland, and Belgium. The company's mission is to promote sustainable mobility by providing EV drivers with renewable energy sourced from solar and wind power. Fastned aims to establish a network of 1000 fast-charging stations in strategic locations, supporting all types of electric vehicles including Tesla Model S/X, Nissan Leaf, BMW i3, and Hyundai Ioniq.
Sol Voltaics
Series C in 2016
Sol Voltaics AB is a nanotechnology company based in Lund, Sweden, established in 2007. It specializes in enhancing the efficiency of solar energy capture and generation by utilizing innovative nanomaterials. The company's flagship product, SolFilm, is a solar panel additive composed of gallium arsenide nanowires that significantly boosts the performance of silicon solar modules. This lightweight photonic film not only converts high-energy sunlight into electricity but is also transparent to infrared light, allowing for further energy conversion by underlying CIGS or silicon cells in a stacked configuration. By integrating these technologies, Sol Voltaics aims to increase conventional photovoltaic module efficiencies by up to 50%, positioning itself at the forefront of the next generation of solar energy solutions.
Sol Voltaics
Grant in 2016
Sol Voltaics AB is a nanotechnology company based in Lund, Sweden, established in 2007. It specializes in enhancing the efficiency of solar energy capture and generation by utilizing innovative nanomaterials. The company's flagship product, SolFilm, is a solar panel additive composed of gallium arsenide nanowires that significantly boosts the performance of silicon solar modules. This lightweight photonic film not only converts high-energy sunlight into electricity but is also transparent to infrared light, allowing for further energy conversion by underlying CIGS or silicon cells in a stacked configuration. By integrating these technologies, Sol Voltaics aims to increase conventional photovoltaic module efficiencies by up to 50%, positioning itself at the forefront of the next generation of solar energy solutions.
Saudi Smart Electronics
Venture Round in 2016
Saudi Smart Electronics is a manufacturer specializing in smart meters that measure electricity consumption. The company's products are designed to notify users of peak electricity consumption periods and are connected to the national grid. This connectivity allows clients to select options for electricity conservation, promoting efficient energy use. By focusing on innovative solutions for monitoring and managing electricity consumption, Saudi Smart Electronics plays a crucial role in enhancing energy efficiency and supporting sustainable practices within the energy sector.
Knowledge Developers
Venture Round in 2015
Knowledge Developers is an information technology firm that specializes in providing a range of services, including software development, web applications, and business management solutions. The company focuses on delivering IT services that facilitate seamless access to information across various devices, thereby enhancing connectivity with existing systems. By addressing the growing demand for software support, Knowledge Developers aims to streamline operations for its clients, ultimately reducing the effort required to manage and access critical information.
Avidity Biosciences
Venture Round in 2014
Avidity Biosciences, Inc. is a biopharmaceutical company based in La Jolla, California, specializing in the development of oligonucleotide-based therapies, particularly through its innovative Antibody Oligonucleotide Conjugates (AOC) platform. This technology aims to address the limitations of traditional oligonucleotide therapies by combining the tissue selectivity of monoclonal antibodies with the precision of oligonucleotide treatments. Avidity's lead product candidate, AOC 1001, targets myotonic dystrophy type 1, a rare genetic muscle disease. In addition to this, the company is advancing multiple programs focused on muscle-related conditions, including muscle atrophy, Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, and Pompe disease. Furthermore, Avidity is expanding its research to include immune and other cell types, positioning itself at the forefront of biopharmaceutical innovation for serious diseases.